Serotonin-1A receptors in the dorsal periaqueductal gray matter mediate the panicolytic-like effect of pindolol and paroxetine combination in the elevated T-maze
| Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
|---|---|
| Data(s) |
19/10/2012
19/10/2012
2011
|
| Resumo |
The beta-adrenergic blocker and 5-HT(1A) receptor antagonist pindolol has been combined with selective serotonin reuptake inhibitors (SSRIs) in patients with depressive and anxiety disorders to shorten the onset of the clinical action and/or increase the proportion of responders. The results of a previous study have shown that pindolol potentiates the panicolytic effect of paroxetine in rats submitted to the elevated T-maze (ETM). Since reported evidence has implicated the 5-HT(1A) receptors of the dorsal periaqueductal gray matter (DPAG) in the panicolytic effect of antidepressants, rats treated with pindolol (5.0 mg/kg, i.p.) and paroxetine (1.5 mg/kg, i.p.) received a previous intra-DPAG injection of the selective 5-HT(1A) antagonist, WAY-100635 (0.4 mu g) and were submitted to the ETM. Pretreatment with WAY-100635 reversed the increase in escape latency, a panicolytic effect, determined by the pindolol-paroxetine combination. These results implicate the 5-HT(1A) receptors of the DPAG in the panicolytic effect of the pindolol-paroxetine combination administered systemically. They also give further preclinical support for the use of this drug combination in the treatment of panic disorder. (C) 2011 Elsevier Ireland Ltd. All rights reserved. CNPq, Brazil CNPq FAEPA |
| Identificador |
NEUROSCIENCE LETTERS, v.495, n.1, p.63-66, 2011 0304-3940 http://producao.usp.br/handle/BDPI/20909 10.1016/j.neulet.2011.03.040 |
| Idioma(s) |
eng |
| Publicador |
ELSEVIER IRELAND LTD |
| Relação |
Neuroscience Letters |
| Direitos |
restrictedAccess Copyright ELSEVIER IRELAND LTD |
| Palavras-Chave | #beta-Adrenergic antagonist #5-HT(1A) receptor #Dorsal periaqueductal gray #Antidepressant #Panic disorder #PLACEBO-CONTROLLED TRIAL #POSTSYNAPTIC 5-HT1A RECEPTORS #GENERALIZED ANXIETY DISORDER #DOUBLE-BLIND #REUPTAKE INHIBITORS #PANIC DISORDER #CONTROLLED-RELEASE #CHRONIC IMIPRAMINE #MAJOR DEPRESSION #RAPHE NUCLEUS #Neurosciences |
| Tipo |
article original article publishedVersion |